Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Oncology Drugs Market 2021
5 November 2021
Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Today, millions of people are living with cancer or have had cancer. Cancer is the second leading cause of death in the United States. The global oncology drugs market is set to grow by US$ 77.33 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 7.4% during the forecast period, according to data and analytics company StrategyHelix. Rising geriatric population, surge in prevalence of cancer, early screening of the cancer, and increase in R&D spending from pharmaceutical & biotechnology companies are expected to boost the market growth in the coming years.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for oncology drugs. The global oncology drugs market is segmented on the basis of drug class, indication, region. By drug class, it is categorized into chemotherapy, hormone therapy, immunotherapy, and targeted therapy. The immunotherapy segment held the largest market share in 2020. By indication, the oncology drugs market is divided into breast cancer, colorectal cancer, lung cancer, multiple myeloma, non-hodgkin’s lymphoma, prostate cancer, and others. The lung cancer segment accounted for the largest market share in 2020. Based on region, the oncology drugs market is divided into North America, Asia Pacific, Europe, and Rest of the World (ROW).
The report has profiled some of the key players of the market such as AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol Myers Squibb (BMS), Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson (J&J), Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the oncology drugs market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Drug class: chemotherapy, hormone therapy, immunotherapy, and targeted therapy
Indication: breast cancer, colorectal cancer, lung cancer, multiple myeloma, non-hodgkin’s lymphoma, prostate cancer, and others
Region: North America, Asia Pacific, Europe, and Rest of the World (ROW)
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the global oncology drugs market
Pinpoint growth sectors and trends for investment
Understand what the future of the global oncology drugs market looks like
Identify the competitive landscape and window of opportunity
Table of Contents
1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Oncology Drugs Market by Drug Class
4.2 Hormone Therapy
4.4 Targeted Therapy
5. Oncology Drugs Market by Indication
5.1 Breast Cancer
5.2 Colorectal Cancer
5.3 Lung Cancer
5.4 Multiple Myeloma
5.5 Non-Hodgkin’s Lymphoma
5.6 Prostate Cancer
6. Oncology Drugs Market by Region
6.1 North America
6.2 Asia Pacific
6.4 Rest Of The World (Row)
7. Company Profiles
7.1 AbbVie Inc.
7.2 Amgen Inc.
7.3 Astellas Pharma Inc.
7.4 AstraZeneca PLC
7.5 Bristol Myers Squibb (BMS)
7.6 Eli Lilly and Company
7.7 F. Hoffmann-La Roche AG
7.8 Johnson & Johnson (J&J)
7.9 Merck KGaA
7.10 Novartis AG
7.11 Pfizer Inc.
7.12 Takeda Pharmaceutical Co., Ltd.
8.1 About StrategyHelix